Sequencing with Microarray Technology--a Powerful New Tool for Molecular Diagnostics (Editorial) Sequencing with Microarray Technology--a Powerful New Tool for Molecular Diagnostics (Editorial)

Sequencing with Microarray Technology--a Powerful New Tool for Molecular Diagnostics (Editorial‪)‬

Clinical Chemistry 2000, Oct, 46, 10

    • 2,99 €
    • 2,99 €

Beschreibung des Verlags

Nucleic acid sequencing is a fundamental technique that was recognized with the 1980 Nobel Prize in Chemistry. The method allows delineation of DNA sequences with extraordinary accuracy and, since its introduction in the 1970s, has undergone many important modifications and improvements. Among these are the achievement of long reads (up to ~1000 by per analysis), better accuracy (related to the discovery of highly versatile and thermostable sequencing enzymes), improved sensitivity with thermocycling protocols (linear amplifications), full automation, higher speed (related to the introduction of thin gels), and substitution of radioactivity with fluorescent and other probes. All of these improvements have allowed scientists to attempt something that was unthinkable 15-20 years ago, i.e., delineation of the complete sequence of the human genome (~3 x [10.sup.9] bp) and genomes of other organisms. We have already witnessed, over the last few years, the release of the complete sequence of simple organisms as well as of more complex ones, the latest being the Drosophila genome (1). We are now very close to the completion of the entire Human Genome Project (2). These achievements represent a triumph of the DNA sequencing methodology. Now that we (almost) know the complete DNA sequences of these organisms and humans, the question arises. How are we to use this information? The next step will be the complete annotation of the human genome, which will include classification of the raw DNA sequence into well-defined gene structures. We will then need to predict and experimentally verify the encoded proteins and their possible biological functions (physiology). Once this is done, we can begin to ask questions about how genomic variation in certain genes (polymorphisms, mutations) can cause or predispose to specific human diseases (pathophysiology). We already have many examples of subtle genetic changes that can cause very serious human diseases, including cystic fibrosis, various forms of anemias, premature atherosclerosis, cancers, neurodegenerative diseases, autoimmune and immunodeficiency syndromes, and other conditions. The number of known disease-related variations will surely increase dramatically with our increasing knowledge of the sequence of the human genome. Already, many researchers and companies are trying to identify all single nucleotide polymorphisms within the human genome.

GENRE
Wissenschaft und Natur
ERSCHIENEN
2000
1. Oktober
SPRACHE
EN
Englisch
UMFANG
11
Seiten
VERLAG
American Association for Clinical Chemistry, Inc.
ANBIETERINFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
GRÖSSE
177,3
 kB
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report) Longitudinal Concentrations of Vitamin [B.Sub.12] and Vitamin [B.Sub.12]-Binding Proteins During Uncomplicated Pregnancy (General Clinical Chemistry) (Clinical Report)
2002
Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs) Multicenter Characterization and Validation of the Intron-8 Poly(T) Tract (IVS8-T) Status in 25 Coriell Cell Repository Cystic Fibrosis Reference Cell Lines for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Assays (Technical Briefs)
2004
Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report) Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable?(Opinion) (Clinical Report)
2001
A Conversation with Elizabeth Blackburn (Interview) A Conversation with Elizabeth Blackburn (Interview)
2009
The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective) The Evolution of Immunoassay As Seen Through the Journal Clinical Chemistry (Aacc 50th Years Anniversary Retrospective)
1998